52
Venkatesan N.
Improvement in Glucose Utilization by Inhibition of Free Fatty Acid (FFA) Oxidation. Diabetes 38 (1989) Suppl. 2, 225A.

53
Vidal H, Beylot M, Comte B, Vega F, Riou J-P.
Vasoactive Intestinal Peptide Stimulates Long-chain Fatty Acid Oxidation and Inhibits Acetyl-coenzyme A Carboxylase Activity in Isolated Rat Enterocytes. J. Biol. Chem. 264 (1989) 4901-4906.

54
Wall SR, Lopaschuk GD.
Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim. Biophys. Acta L. 1006 (1989) 97-103.

55
Weikert G, Hübinger A, Wolf HPO, Gries FA.
Der Effekt von Etomoxir auf die Insulinsensitivität bei Typ-II-Diabetikern. Akt. Endokr. Stoffw. 10 (1989) Abstrakt X. Intern. Donausymposium, Dresden.

56
Wolf HPO, Luehmann R, Wurst W, Radtke H.
Analyse der Wirksamkeit von Etomoxir bei Typ-2-Diabetikern aus Phase II-Studien. Akt. Endokr. Stoffw. 10 (1989) Abstrakt X. Intern. Donausymposium, Dresden.

57
Wolf HPO.
A Promising New Therapeutic Approach in Diabetes Mellitus by Inhibition of Carnitine Palmitoyltransferase I (CPT I). Eur. J. Clin. Invest. 19 (1989) no 2, A73.

58
Barnett M, Collier GR, O´Dea K.
The effect of inhibiting fatty acid oxidation on glucose tolerance in sand rats. Proc. Nutr. Soc. Aust. 15 (1990) 169.

59
Belloiu DD.
Biochemical considerations regarding cellular regulation through messenger and allosteric systems. Rev. Roum. Med. – Endocrinol. 28 (1990) 3-13.

60
Berg A, Walz R, Frey I, Jakob E, Baumstark MW, Keul J.
Influence of carnitine and CAT-I-inhibitor application on aerobic performance in endurance-trained males. VII International Congress on Neuromuscular Diseases, Munich, Germany, September 1990.

61
Berg A, Walz R, Jakob E, Keul J.
Einfluß von Carnitin- und CAT-I-Inhibitor-Gabe auf spiroergometrische Meßgrößenen unter Ausdauerbelastung. 32. Sportärztekonkress, München 1990.